Academic Journal
Persistence of immunity following 2-dose priming with a 10-valent pneumococcal conjugate vaccine at 6 and 10 weeks or 6 and 14 weeks of age in Nepalese toddlers
| Τίτλος: | Persistence of immunity following 2-dose priming with a 10-valent pneumococcal conjugate vaccine at 6 and 10 weeks or 6 and 14 weeks of age in Nepalese toddlers |
|---|---|
| Συγγραφείς: | Gurung, M, Bijukchhe, SM, Hariri, P, Voysey, M, Kandasamy, R, Thorson, S, Maskey, P, Pandit, R, Shrestha, B, Gautam, MC, Maharjan, M, Lama, L, Acharya, B, Basi, R, K C, M, O'Reilly, P, Shrestha, S, Ansari, I, Shah, GP, Kelly, S, O'Brien, KL, Goldblatt, D, Kelly, DF, Murdoch, DR, Pollard, AJ |
| Στοιχεία εκδότη: | Lippincott, Williams & Wilkins |
| Έτος έκδοσης: | 2021 |
| Συλλογή: | Oxford University Research Archive (ORA) |
| Περιγραφή: | Background: The pneumococcal conjugate vaccine has had a substantial impact on invasive pneumococcal disease. Previously, we compared immunity following vaccination with the 10-valent pneumococcal conjugate vaccine (PCV10) administered at 2 slightly different schedules: at 6 and 10 weeks of age, and at 6 and 14 weeks of age, both followed by a 9-month booster. In this study, we followed up those participants to evaluate the medium-term persistence of serotype-specific pneumococcal immunity at 2-3 years of age. Method: Children from the previous studies were contacted and after taking informed consent from their parents, blood samples and nasopharyngeal swabs were collected. Serotype-specific IgG antibody concentrations were determined by enzyme-linked immunosorbent assay, for the 10 vaccine serotypes, at a WHO pneumococcal serology reference laboratory. Findings: Two hundred twenty of the 287 children who completed the primary study returned at 2–3 years of age to provide a blood sample and nasopharyngeal swab. The nasopharyngeal carriage rate of PCV10 serotypes in the 6 + 14 group was higher than the 6 + 10 group (13.4% vs. 1.9%). Nevertheless, the proportion of toddlers with serum pneumococcal serotype-specific IgG greater than or equal to 0.35 µg/mL was comparable for all PCV10 serotypes between the 6 + 10 week and 6 + 14 week groups. Similarly, the geometric mean concentrations of serum pneumococcal serotype-specific IgG levels were similar in the 2 groups for all serotypes, except for serotype 19F which was 32% lower in the 6 + 10 group than the 6 + 14 group. Conclusion: Immunization with PCV10 at 6 + 10 weeks or 6 + 14 weeks, with a booster at 9 months in each case, results in similar persistence of serotype-specific antibody at 2-3 years of age. Thus, protection from pneumococcal disease is expected to be similar when either schedule is used. |
| Τύπος εγγράφου: | article in journal/newspaper |
| Γλώσσα: | English |
| Relation: | https://doi.org/10.1097/inf.0000000000003223 |
| DOI: | 10.1097/inf.0000000000003223 |
| Διαθεσιμότητα: | https://doi.org/10.1097/inf.0000000000003223 https://ora.ox.ac.uk/objects/uuid:7679d923-e6be-4f3b-8a50-b8f607d01165 |
| Rights: | info:eu-repo/semantics/openAccess ; CC Attribution-NonCommercial (CC BY-NC) |
| Αριθμός Καταχώρησης: | edsbas.C551F161 |
| Βάση Δεδομένων: | BASE |
| DOI: | 10.1097/inf.0000000000003223 |
|---|